Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

21.88 -0.13 (-0.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 837,921
Open 22.30
Bid (Size) 21.83 (2)
Ask (Size) 22.19 (1)
Prev. Close 22.01
Today's Range 21.82 - 22.30
52wk Range 17.23 - 28.56
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
GENMAB A/S -SP ADR (NASDAQ:GMAB) - A Biotech Stock With Strong Growth and Reasonable Valuation
GENMAB A/S (NASDAQ:GMAB) is a biotech stock with strong earnings growth, high profitability, and a reasonable valuation, making it a candidate for long-term investors following Peter Lynch's strategy. 
Via Chartmill
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)
From Genmab
Via Business Wire

Performance

YTD
+4.2%
+4.2%
1 Month
-0.7%
-0.7%
3 Month
+9.2%
+9.2%
6 Month
+3.1%
+3.1%
1 Year
-18.4%
-18.4%

More News

Read More
GENMAB A/S -SP ADR (NASDAQ:GMAB) – A Strong Candidate for GARP Investors
Via Chartmill
Breaking Down Genmab: 4 Analysts Share Their Views
Via Benzinga
Why Genmab Stock Smashed It on Monday
Via The Motley Fool
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial
From Genmab A/S
Via Business Wire
GENMAB A/S -SP ADR (NASDAQ:GMAB) – A Strong Growth Stock Showing Technical Breakout Potential
Via Chartmill
Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
From Genmab A/S
Via Business Wire
GENMAB A/S -SP ADR (NASDAQ:GMAB) - A Strong Candidate for Affordable Growth Investors
Via Chartmill
GENMAB A/S -SP ADR (NASDAQ:GMAB) - A Strong Candidate for GARP Investors
Via Chartmill
Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress
From Genmab A/S
Via Business Wire
GENMAB A/S -SP ADR (NASDAQ:GMAB) appears to be flying under the radar despite its strong fundamentals.
Via Chartmill
Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
From Genmab A/S
Via Business Wire
GENMAB A/S -SP ADR (NASDAQ:GMAB): A Strong Affordable Growth Stock
Via Chartmill
GENMAB A/S -SP ADR (NASDAQ:GMAB): a strong growth stock preparing for the next leg up?.
Via Chartmill
Why Peter Lynch may take an interest in GENMAB A/S -SP ADR (NASDAQ:GMAB)
Via Chartmill
Despite its growth, GENMAB A/S -SP ADR (NASDAQ:GMAB) remains within the realm of affordability.
Via Chartmill
Genmab Stock Rises On Strong Darzalex Sales In Q1: Retail Remains Extremely Bullish
Via Stocktwits
Topics Stocks
What Analysts Are Saying About Genmab Stock
Via Benzinga
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer
From Genmab A/S
Via Business Wire
Does GENMAB A/S -SP ADR (NASDAQ:GMAB) match Peter Lynch’s “Invest in What You Know” philosophy?
Via Chartmill
Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer
Via Benzinga
TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy
From Genmab A/S
Via Business Wire
Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer
From Genmab
Via Business Wire
Coinbase, Apple And Robinhood Are Among Top Large-Cap Losers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio?
Via Benzinga

Frequently Asked Questions

Is Genmab A/S - American Depositary Shares publicly traded?
Yes, Genmab A/S - American Depositary Shares is publicly traded.
What exchange does Genmab A/S - American Depositary Shares trade on?
Genmab A/S - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Genmab A/S - American Depositary Shares?
The ticker symbol for Genmab A/S - American Depositary Shares is GMAB on the Nasdaq Stock Market
What is the current price of Genmab A/S - American Depositary Shares?
The current price of Genmab A/S - American Depositary Shares is 21.88
When was Genmab A/S - American Depositary Shares last traded?
The last trade of Genmab A/S - American Depositary Shares was at 07/18/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.